Delving into the Latest Updates on Aju Pharm Co. Ltd. with Synapse

A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase 4 Study to Evaluate the Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

This study is planned to Evaluate the Efficacy and Safety of OM-89 in Patients with Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

开始日期2023-12-20

申办/合作机构

Aju Pharm Co. Ltd.

[+1]

NCT06291194 / Recruiting临床3期

The Purpose of This Clinical Study is to Prove That the Test Drug (AJU-S56 5%) is Superior to the Control Drug After 24 Weeks of Administration to Patients Who Have Moderate or Severe Dry Eye Syndrome

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.

开始日期2023-11-10

申办/合作机构

Aju Pharm Co. Ltd.

[+1]

NCT06416865 / Recruiting临床3期

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment

A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately controlled on C52R1L treament

开始日期2022-06-27

申办/合作机构

Aju Pharm Co. Ltd.

100 项与 Aju Pharm Co. Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Aju Pharm Co. Ltd. 相关的专利（医药）

登录后查看更多信息

100 项与 Aju Pharm Co. Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Aju Pharm Co. Ltd. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床3期

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

达格列净/利格列汀 ( DPP-4 x SGLT2 )	2型糖尿病更多	临床3期
缬沙坦/氨氯地平/氯噻酮 ( AT1R x NCC x VDCCs )	原发性高血压更多	临床3期